The NT5C3A Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population with targeted disruption of the human NT5C3A gene in the Raji B-lymphoblastoid cell line. This polyclonal knockout model provides a genetically heterogeneous system for studying cytosolic 5′-nucleotidase IIIA function, avoiding clonal artifacts. It enables comprehensive dissection of pyrimidine nucleotide metabolism and nucleoside analog sensitivity in a B-cell context.
Raji is an Epstein-Barr virus (EBV)-positive B-cell line established from a Burkitt lymphoma patient, widely employed to investigate apoptosis, NF-??B signaling, and B-cell receptor pathways. Its well-characterized signaling network, rapid proliferation, and high nucleotide turnover render it an optimal platform for exploring metabolic dependencies in B-cell malignancies and for modeling lymphomagenesis linked to viral oncogenesis.
The NT5C3A gene product, cytosolic pyrimidine 5′-nucleotidase IIIA, catalyzes the dephosphorylation of UMP and CMP to uridine and cytidine, underpinning pyrimidine salvage and homeostasis. Its expression is regulated by cell cycle-associated transcription factors E2F and MYC. The enzyme acts as a homodimer and potentially interacts with other metabolic regulators such as UCK1, CDA, and DCTD. Downstream, uridine and cytidine are converted to UTP and CTP via salvage kinases and incorporated into RNA and DNA. Disruption of NT5C3A leads to accumulation of UMP and CMP, diminished uridine and cytidine, and ensuing nucleotide pool imbalances that sensitize cells to apoptosis. Moreover, knockout alters the metabolic activation and therapeutic efficacy of pyrimidine analog prodrugs like gemcitabine and 5-fluorouracil.
In the Raji background, NT5C3A loss provides a platform to interrogate the integration of pyrimidine metabolism with oncogenic signaling. Raji??s dependence on robust nucleotide synthesis for proliferation renders it susceptible to disruptions in pyrimidine balance, amplifying replication stress and modulating responses to nucleoside-based chemotherapy. This model also permits investigation of how EBV-encoded factors may converge on nucleotide metabolism, offering insights into viral lymphomagenesis and potential therapeutic vulnerabilities.
This knockout cell population is suited for applications including mechanistic studies of pyrimidine metabolism, dissection of drug resistance pathways, and preclinical evaluation of nucleoside analog therapies. Experimental readouts commonly incorporate HPLC or LC-MS?Cbased nucleotide profiling, MTT or ATP viability assays, Western blot detection of apoptotic markers (cleaved caspase-3, PARP), RT-qPCR quantitation of metabolic enzymes, flow cytometric cell cycle analysis, and intracellular monitoring of analog triphosphate accumulation. By leveraging this model, researchers can investigate NT5C3A function in B-cell lymphoma and develop strategies to counter acquired drug resistance. For additional details, please contact Ascent Research.
